China Resources Double Crane: Some of the company's drugs are expected to be selected for the national organization's centralized procurement of drugs for continuation of procurement.

Announcement of China Resources Double-Crane: the company and some of its subsidiaries participated in the national organization's centralized procurement of medicines. Some of the medicines are expected to be selected. The main medicines expected to be selected include Valsartan Hydrochlorothiazide Tablets from China Resources Double-Crane Pharmaceutical Co., Ltd., Nitrendipine Sustained-Release Tablets, Nitrendipine Controlled-Release Tablets, and Irbesartan Dispersible Tablets from China Resources Lemin Pharmaceutical Co., Ltd., as well as Enoxaparin Sodium Injection from Dongying Tiandong Pharmaceutical Co., Ltd. In 2024, the sales revenue of Valsartan Hydrochlorothiazide Tablets was 517 million yuan, accounting for 4.61% of the annual operating income in 2024; the sales revenue of Nitrendipine Controlled-Release Tablets was 147 million yuan, accounting for 1.31% of the annual operating income in 2024; the sales revenue of Enoxaparin Sodium Injection was 128 million yuan, accounting for 1.14% of the annual operating income in 2024; the sales revenue of Nitrendipine Sustained-Release Tablets was 118 million yuan, accounting for 1.05% of the annual operating revenue in 2024; the sales revenue of Irbesartan Dispersible Tablets was 110 million yuan, accounting for 0.98% of the annual operating income in 2024.